At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 2, 2026 at 07:05 ET
uniQure reported financial results for 2025, showing a revenue decline to $16.1 million and a reduced net loss of $199.0 million, or $3.46 per share, compared to $239.6 million in 2024. The company highlighted clinical progress in its gene therapy pipeline, particularly durable data for AMT-130 in Huntington’s disease, but disclosed that the FDA rejected the use of external controls for approval and mandated a randomized Phase III trial. With $622.5 million in cash, uniQure is funded into 2029.
- Revenue decreased to $16.1 million in 2025 from $27.1 million in 2024, driven by lower collaboration and contract manufacturing revenue.
- Net loss narrowed to $199.0 million ($3.46/share) from $239.6 million ($4.92/share) in 2024.
- FDA rejected approval pathway for AMT-130 based on single-arm trial with external controls; required a randomized, sham-controlled Phase III study.
- AMT-130 showed statistically significant 75% slowing in disease progression at 36 months in high-dose patients.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access